Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1
Immunotherapy is a breakthrough in human cancer therapy and has become a major concern in veterinary oncology. However, in cats, many unclear points of the tumor microenvironment exist, including immune checkpoint molecules. A reason is that very few monoclonal antibodies have been proven to react w...
Gespeichert in:
| Veröffentlicht in: | Journal of Veterinary Medical Science 2023, Vol.85(6), pp.592-600 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 600 |
|---|---|
| container_issue | 6 |
| container_start_page | 592 |
| container_title | Journal of Veterinary Medical Science |
| container_volume | 85 |
| creator | NISHIBORI, Shoma SAKURAI, Masashi KAGAWA, Yumiko UCHIDA, Kazuyuki NAKAGAWA, Takayuki IGASE, Masaya MIZUNO, Takuya |
| description | Immunotherapy is a breakthrough in human cancer therapy and has become a major concern in veterinary oncology. However, in cats, many unclear points of the tumor microenvironment exist, including immune checkpoint molecules. A reason is that very few monoclonal antibodies have been proven to react with feline molecules. Therefore, this study investigated whether anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8, which is currently commercially available, can also recognize feline PD-L1 by flow cytometry, immunoprecipitation, and immunohistochemical (IHC) staining. We confirmed that the antibody’s specificity by flow cytometry and immunoprecipitation using NIH3T3 cells transfected with feline PD-L1. Additionally, we revealed that PD-L1 was expressed on the surface of some feline cell lines by flow cytometry and clone 28-8 antibody unbound to the cells where feline PD-L1 was knocked out. Furthermore, IHC analysis revealed that PD-L1 was expressed in macrophages in the spleen and lymph nodes from healthy cats and mast cell tumor cells. Therefore, we indicated that the clone 28-8 antibody is a valuable tool in detecting feline PD-L1, and further analysis of tumor tissues is expected in the future. |
| doi_str_mv | 10.1292/jvms.23-0003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10315546</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2811215783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c619t-1a4962f902e32d0cb0bffb8d0e69c3d5e2a37a78376f06038fe5931aa2c359b53</originalsourceid><addsrcrecordid>eNpdkc2P0zAQxS0EYsvCjTOyxGWRNos_4iQ-ISifUiU4wNmaOE7qKrGL7VQqfz3xtlTAxZZmfvM0bx5Czym5o0yy17vDFO8YLwgh_AFaUV7WRV1y-RCtiKRVUTNBrtCTGHeEMFpW8jG64jUVpCJ8hX6tg4-xCAZ0sgebjtj3GFyyxXaewOF98EOAaTId1mYccWcgbfFoB3Adpvjm2_tiQ1_hyTuvR-9gvB9ufXe8xblgMGuKBsMA1sWEezPapXY_9RQ96mGM5tn5v0Y_Pn74vv5cbL5--rJ-uyl0RWUqKJSyYr0kzHDWEd2Stu_bpiOmkpp3wjDgNdQNr6s-e2p6IySnAExzIVvBr9Gbk-5-bhcf2rgUYFT7YCcIR-XBqn87zm7V4A-KEk6FKKtF4easEPzP2cSkJhvzOcAZP0fFGkoZFcsOC_ryP3Tn57DcJVN8yaJqWKZuT5TO1w-mv2xDicqpqpyqYlzlVBf8xd8OLvCfGBfg3QnYxQSDuQAQktWjOak1QlX5OatemnoLQRnHfwPVgbTf</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2837256823</pqid></control><display><type>article</type><title>Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>NISHIBORI, Shoma ; SAKURAI, Masashi ; KAGAWA, Yumiko ; UCHIDA, Kazuyuki ; NAKAGAWA, Takayuki ; IGASE, Masaya ; MIZUNO, Takuya</creator><creatorcontrib>NISHIBORI, Shoma ; SAKURAI, Masashi ; KAGAWA, Yumiko ; UCHIDA, Kazuyuki ; NAKAGAWA, Takayuki ; IGASE, Masaya ; MIZUNO, Takuya</creatorcontrib><description>Immunotherapy is a breakthrough in human cancer therapy and has become a major concern in veterinary oncology. However, in cats, many unclear points of the tumor microenvironment exist, including immune checkpoint molecules. A reason is that very few monoclonal antibodies have been proven to react with feline molecules. Therefore, this study investigated whether anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8, which is currently commercially available, can also recognize feline PD-L1 by flow cytometry, immunoprecipitation, and immunohistochemical (IHC) staining. We confirmed that the antibody’s specificity by flow cytometry and immunoprecipitation using NIH3T3 cells transfected with feline PD-L1. Additionally, we revealed that PD-L1 was expressed on the surface of some feline cell lines by flow cytometry and clone 28-8 antibody unbound to the cells where feline PD-L1 was knocked out. Furthermore, IHC analysis revealed that PD-L1 was expressed in macrophages in the spleen and lymph nodes from healthy cats and mast cell tumor cells. Therefore, we indicated that the clone 28-8 antibody is a valuable tool in detecting feline PD-L1, and further analysis of tumor tissues is expected in the future.</description><identifier>ISSN: 0916-7250</identifier><identifier>EISSN: 1347-7439</identifier><identifier>DOI: 10.1292/jvms.23-0003</identifier><identifier>PMID: 37150603</identifier><language>eng</language><publisher>Japan: JAPANESE SOCIETY OF VETERINARY SCIENCE</publisher><subject>Animals ; Antibodies, Monoclonal ; antibody ; Apoptosis ; B7-H1 Antigen ; Cancer therapies ; Cats ; Cell death ; Clinical Pathology ; Clone Cells - chemistry ; Clone Cells - metabolism ; Cross-reactivity ; feline ; Flow cytometry ; Immune checkpoint ; Immunohistochemistry ; Immunoprecipitation ; Immunotherapy ; Ligands ; Lymph nodes ; Macrophages ; Mice ; Monoclonal antibodies ; NIH 3T3 Cells ; PD-L1 protein ; programmed cell death ligand 1 ; Tumor cells ; Tumor microenvironment ; Tumors</subject><ispartof>Journal of Veterinary Medical Science, 2023, Vol.85(6), pp.592-600</ispartof><rights>2023 by the Japanese Society of Veterinary Science</rights><rights>2023. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 The Japanese Society of Veterinary Science 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c619t-1a4962f902e32d0cb0bffb8d0e69c3d5e2a37a78376f06038fe5931aa2c359b53</citedby><cites>FETCH-LOGICAL-c619t-1a4962f902e32d0cb0bffb8d0e69c3d5e2a37a78376f06038fe5931aa2c359b53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315546/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315546/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1876,4009,27901,27902,27903,53768,53770</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37150603$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NISHIBORI, Shoma</creatorcontrib><creatorcontrib>SAKURAI, Masashi</creatorcontrib><creatorcontrib>KAGAWA, Yumiko</creatorcontrib><creatorcontrib>UCHIDA, Kazuyuki</creatorcontrib><creatorcontrib>NAKAGAWA, Takayuki</creatorcontrib><creatorcontrib>IGASE, Masaya</creatorcontrib><creatorcontrib>MIZUNO, Takuya</creatorcontrib><title>Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1</title><title>Journal of Veterinary Medical Science</title><addtitle>J. Vet. Med. Sci.</addtitle><description>Immunotherapy is a breakthrough in human cancer therapy and has become a major concern in veterinary oncology. However, in cats, many unclear points of the tumor microenvironment exist, including immune checkpoint molecules. A reason is that very few monoclonal antibodies have been proven to react with feline molecules. Therefore, this study investigated whether anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8, which is currently commercially available, can also recognize feline PD-L1 by flow cytometry, immunoprecipitation, and immunohistochemical (IHC) staining. We confirmed that the antibody’s specificity by flow cytometry and immunoprecipitation using NIH3T3 cells transfected with feline PD-L1. Additionally, we revealed that PD-L1 was expressed on the surface of some feline cell lines by flow cytometry and clone 28-8 antibody unbound to the cells where feline PD-L1 was knocked out. Furthermore, IHC analysis revealed that PD-L1 was expressed in macrophages in the spleen and lymph nodes from healthy cats and mast cell tumor cells. Therefore, we indicated that the clone 28-8 antibody is a valuable tool in detecting feline PD-L1, and further analysis of tumor tissues is expected in the future.</description><subject>Animals</subject><subject>Antibodies, Monoclonal</subject><subject>antibody</subject><subject>Apoptosis</subject><subject>B7-H1 Antigen</subject><subject>Cancer therapies</subject><subject>Cats</subject><subject>Cell death</subject><subject>Clinical Pathology</subject><subject>Clone Cells - chemistry</subject><subject>Clone Cells - metabolism</subject><subject>Cross-reactivity</subject><subject>feline</subject><subject>Flow cytometry</subject><subject>Immune checkpoint</subject><subject>Immunohistochemistry</subject><subject>Immunoprecipitation</subject><subject>Immunotherapy</subject><subject>Ligands</subject><subject>Lymph nodes</subject><subject>Macrophages</subject><subject>Mice</subject><subject>Monoclonal antibodies</subject><subject>NIH 3T3 Cells</subject><subject>PD-L1 protein</subject><subject>programmed cell death ligand 1</subject><subject>Tumor cells</subject><subject>Tumor microenvironment</subject><subject>Tumors</subject><issn>0916-7250</issn><issn>1347-7439</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc2P0zAQxS0EYsvCjTOyxGWRNos_4iQ-ISifUiU4wNmaOE7qKrGL7VQqfz3xtlTAxZZmfvM0bx5Czym5o0yy17vDFO8YLwgh_AFaUV7WRV1y-RCtiKRVUTNBrtCTGHeEMFpW8jG64jUVpCJ8hX6tg4-xCAZ0sgebjtj3GFyyxXaewOF98EOAaTId1mYccWcgbfFoB3Adpvjm2_tiQ1_hyTuvR-9gvB9ufXe8xblgMGuKBsMA1sWEezPapXY_9RQ96mGM5tn5v0Y_Pn74vv5cbL5--rJ-uyl0RWUqKJSyYr0kzHDWEd2Stu_bpiOmkpp3wjDgNdQNr6s-e2p6IySnAExzIVvBr9Gbk-5-bhcf2rgUYFT7YCcIR-XBqn87zm7V4A-KEk6FKKtF4easEPzP2cSkJhvzOcAZP0fFGkoZFcsOC_ryP3Tn57DcJVN8yaJqWKZuT5TO1w-mv2xDicqpqpyqYlzlVBf8xd8OLvCfGBfg3QnYxQSDuQAQktWjOak1QlX5OatemnoLQRnHfwPVgbTf</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>NISHIBORI, Shoma</creator><creator>SAKURAI, Masashi</creator><creator>KAGAWA, Yumiko</creator><creator>UCHIDA, Kazuyuki</creator><creator>NAKAGAWA, Takayuki</creator><creator>IGASE, Masaya</creator><creator>MIZUNO, Takuya</creator><general>JAPANESE SOCIETY OF VETERINARY SCIENCE</general><general>Japan Science and Technology Agency</general><general>The Japanese Society of Veterinary Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QR</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2023</creationdate><title>Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1</title><author>NISHIBORI, Shoma ; SAKURAI, Masashi ; KAGAWA, Yumiko ; UCHIDA, Kazuyuki ; NAKAGAWA, Takayuki ; IGASE, Masaya ; MIZUNO, Takuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c619t-1a4962f902e32d0cb0bffb8d0e69c3d5e2a37a78376f06038fe5931aa2c359b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal</topic><topic>antibody</topic><topic>Apoptosis</topic><topic>B7-H1 Antigen</topic><topic>Cancer therapies</topic><topic>Cats</topic><topic>Cell death</topic><topic>Clinical Pathology</topic><topic>Clone Cells - chemistry</topic><topic>Clone Cells - metabolism</topic><topic>Cross-reactivity</topic><topic>feline</topic><topic>Flow cytometry</topic><topic>Immune checkpoint</topic><topic>Immunohistochemistry</topic><topic>Immunoprecipitation</topic><topic>Immunotherapy</topic><topic>Ligands</topic><topic>Lymph nodes</topic><topic>Macrophages</topic><topic>Mice</topic><topic>Monoclonal antibodies</topic><topic>NIH 3T3 Cells</topic><topic>PD-L1 protein</topic><topic>programmed cell death ligand 1</topic><topic>Tumor cells</topic><topic>Tumor microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NISHIBORI, Shoma</creatorcontrib><creatorcontrib>SAKURAI, Masashi</creatorcontrib><creatorcontrib>KAGAWA, Yumiko</creatorcontrib><creatorcontrib>UCHIDA, Kazuyuki</creatorcontrib><creatorcontrib>NAKAGAWA, Takayuki</creatorcontrib><creatorcontrib>IGASE, Masaya</creatorcontrib><creatorcontrib>MIZUNO, Takuya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Chemoreception Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Veterinary Medical Science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NISHIBORI, Shoma</au><au>SAKURAI, Masashi</au><au>KAGAWA, Yumiko</au><au>UCHIDA, Kazuyuki</au><au>NAKAGAWA, Takayuki</au><au>IGASE, Masaya</au><au>MIZUNO, Takuya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1</atitle><jtitle>Journal of Veterinary Medical Science</jtitle><addtitle>J. Vet. Med. Sci.</addtitle><date>2023</date><risdate>2023</risdate><volume>85</volume><issue>6</issue><spage>592</spage><epage>600</epage><pages>592-600</pages><artnum>23-0003</artnum><issn>0916-7250</issn><eissn>1347-7439</eissn><abstract>Immunotherapy is a breakthrough in human cancer therapy and has become a major concern in veterinary oncology. However, in cats, many unclear points of the tumor microenvironment exist, including immune checkpoint molecules. A reason is that very few monoclonal antibodies have been proven to react with feline molecules. Therefore, this study investigated whether anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8, which is currently commercially available, can also recognize feline PD-L1 by flow cytometry, immunoprecipitation, and immunohistochemical (IHC) staining. We confirmed that the antibody’s specificity by flow cytometry and immunoprecipitation using NIH3T3 cells transfected with feline PD-L1. Additionally, we revealed that PD-L1 was expressed on the surface of some feline cell lines by flow cytometry and clone 28-8 antibody unbound to the cells where feline PD-L1 was knocked out. Furthermore, IHC analysis revealed that PD-L1 was expressed in macrophages in the spleen and lymph nodes from healthy cats and mast cell tumor cells. Therefore, we indicated that the clone 28-8 antibody is a valuable tool in detecting feline PD-L1, and further analysis of tumor tissues is expected in the future.</abstract><cop>Japan</cop><pub>JAPANESE SOCIETY OF VETERINARY SCIENCE</pub><pmid>37150603</pmid><doi>10.1292/jvms.23-0003</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0916-7250 |
| ispartof | Journal of Veterinary Medical Science, 2023, Vol.85(6), pp.592-600 |
| issn | 0916-7250 1347-7439 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10315546 |
| source | J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Animals Antibodies, Monoclonal antibody Apoptosis B7-H1 Antigen Cancer therapies Cats Cell death Clinical Pathology Clone Cells - chemistry Clone Cells - metabolism Cross-reactivity feline Flow cytometry Immune checkpoint Immunohistochemistry Immunoprecipitation Immunotherapy Ligands Lymph nodes Macrophages Mice Monoclonal antibodies NIH 3T3 Cells PD-L1 protein programmed cell death ligand 1 Tumor cells Tumor microenvironment Tumors |
| title | Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T08%3A44%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cross-reactivity%20of%20anti-human%20programmed%20cell%20death%20ligand%201%20(PD-L1)%20monoclonal%20antibody,%20clone%2028-8%20against%20feline%20PD-L1&rft.jtitle=Journal%20of%20Veterinary%20Medical%20Science&rft.au=NISHIBORI,%20Shoma&rft.date=2023&rft.volume=85&rft.issue=6&rft.spage=592&rft.epage=600&rft.pages=592-600&rft.artnum=23-0003&rft.issn=0916-7250&rft.eissn=1347-7439&rft_id=info:doi/10.1292/jvms.23-0003&rft_dat=%3Cproquest_pubme%3E2811215783%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2837256823&rft_id=info:pmid/37150603&rfr_iscdi=true |